| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal HST20: Selumetinib for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and over |
|
Medicine details |
|
| Medicine name | selumetinib (Koselugo®) |
| Formulation | 10 mg and 25 mg hard capsule |
| Reference number | 4218 |
| Indication | Monotherapy is indicated for the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in paediatric patients with neurofibromatosis type 1 (NF1) aged 3 years and above |
| Company | AstraZeneca UK Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 13/05/2021 |
| NICE guidance | |
| Commercial arrangement | PAS |